Azacitidine

Azacitidine
Clinical data
Trade names	Vidaza, Azadine, Onureg
Other names	5-Azacytidine, Azacytidine, Ladakamycin, 4-Amino-1-β-D-ribofuranosyl-s-triazin-2(1H)-one, U-18496, CC-486
AHFS/Drugs.com	Monograph
MedlinePlus	a607068
License data	US DailyMed: Azacitidine;
Pregnancy; category	AU: X (High risk);
Routes of; administration	Subcutaneous, intravenous, by mouth
ATC code	L01BC07 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Elimination half-life	4 hr.
Identifiers
	IUPAC name 4-Amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one;
CAS Number	320-67-2 ;
PubChem CID	9444;
IUPHAR/BPS	6796;
DrugBank	DB00928 ;
ChemSpider	9072 ;
UNII	M801H13NRU;
KEGG	D03021 ;
ChEBI	CHEBI:2038 ;
ChEMBL	ChEMBL1489 ;
CompTox Dashboard (EPA)	DTXSID9020116 ;
ECHA InfoCard	100.005.711
Chemical and physical data
Formula	C8H12N4O5
Molar mass	244.207 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1/N=C(\N=C/N1[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)CO)N;
	InChI InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1 ; Key:NMUSYJAQQFHJEW-KVTDHHQDSA-N ;
	(verify)

Azacitidine, sold under the brand name Vidaza among others, is a medication used for the treatment of myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia. It is a chemical analog of cytidine, a nucleoside in DNA and RNA. Azacitidine and its deoxy derivative, decitabine (also known as 5-aza-2′-deoxycytidine) were first synthesized in Czechoslovakia as potential chemotherapeutic agents for cancer.

The most common adverse reactions in children with juvenile myelomonocytic leukemia include pyrexia, rash, upper respiratory tract infection, and anemia.